#BEGIN_DRUGCARD DB00558

# AHFS_Codes:
08:18.28

# ATC_Codes:
J05AH01

# Absorption:
Absolute bioavailability is very low following oral administration (2%).  Following oral inhalation, bioavailability is 4% to 17%.

# Biotransformation:
Not metabolized

# Brand_Mixtures:
Not Available

# Brand_Names:
Relenza

# CAS_Registry_Number:
139110-80-8

# ChEBI_ID:
50663

# Chemical_Formula:
C12H20N4O7

# Chemical_IUPAC_Name:
(2R,3R,4S)-4-[(diaminomethylidene)amino]-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2240863

# Description:
A guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem]

# Dosage_Forms:
Powder	Respiratory (inhalation)

# Drug_Category:
Antiviral Agents
Enzyme Inhibitors
Neuraminidase Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
18582202	Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K: Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis. 2008 Aug 1;47(3):339-45.
18694948	Hata K, Koseki K, Yamaguchi K, Moriya S, Suzuki Y, Yingsakmongkon S, Hirai G, Sodeoka M, von Itzstein M, Miyagi T: Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases. Antimicrob Agents Chemother. 2008 Aug 11.
4362431	Meindl P, Bodo G, Palese P, Schulman J, Tuppy H: Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology. 1974 Apr;58(2):457-63.
8502295	von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, et al.: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993 Jun 3;363(6428):418-23.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Zanamivir

# HET_ID:
ZMR

# Half_Life:
2.5-5.1 hours

# InChI_Identifier:
InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

# InChI_Key:
InChIKey=ARAIBEBZBOPLMB-UFGQHTETSA-N

# Indication:
For the prevention and treatment of influenza A and B.

# KEGG_Compound_ID:
C08095

# KEGG_Drug_ID:
D00902

# LIMS_Drug_ID:
558

# Mechanism_Of_Action:
The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
332.3098

# Molecular_Weight_Mono:
332.133199014

# Organisms_Affected:
Influenza A virus
Influenza B virus

# PDB_Experimental_ID:
2BAT

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164740891

# Pharmacology:
Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.

# Predicted_LogP_Hydrophobicity:
-2.3

# Predicted_LogS:
-1.7

# Predicted_Water_Solubility:
7.31e+00 g/l

# Primary_Accession_No:
DB00558

# Protein_Binding:
Zanamivir has limited plasma protein binding (<10%).

# PubChem_Compound_ID:
60855

# PubChem_Substance_ID:
46508581

# RxList_Link:
http://www.rxlist.com/cgi/generic2/zanam.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00378

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]1(OC(=C[C@H](N=C(N)N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
GANA
GNA
Modified sialic acid
ZMR
Zanamavir

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:27 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Zanamivir

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Virion
apical cell membrane
single-pass type II membrane protein (
virion membrane. Cell membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11413297	Murrell MT, Porotto M, Greengard O, Poltoratskaia N, Moscona A: A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity. J Virol. 2001 Jul;75(14):6310-20.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
14575130	Mungall BA, Xu X, Klimov A: Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays. Avian Dis. 2003;47(3 Suppl):1141-4.
15828835	Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, McKimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY, Tucker SP: Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem. 2005 Apr 21;48(8):2964-71.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
K01150

# Drug_Target_1_GenBank_ID_Protein:
324460

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
NA

# Drug_Target_1_Gene_Sequence:
>1410 bp
ATGAATCCAAATCAAAAGATAATAACAATTGGCTCTGTCTCTCTCACCATTGCAACAATA
TGCTTCCTTATGCAAATTGCCATCCTGGTAACTACTGTAACATTGCATTTCAAGCAATAT
GAGTGCAGCTCCCCCCCAAACAACCAAGTAATGCCGTGTGAACCAATAATAATAGAAAGA
AACATAACAGAGATAGTGTATTTGACTAACACCACCATAGACAAAGAGATATGCCCCAAA
TTAGTGGAATACAGAAATTGGTCAAAGCCGCAATGTAAAATTACAGGATTTGCACCTTTT
TCTAAGGACAATTCAATTCGGCTTTCTGCTGGTGGGGGCATTTGGGTGACGAGAGAACCT
TATGTGTCATGCGATCCTGGCAAGTGTTATCAATTTGCACTCGGGCAGGGGACCACACTA
GACAACAAGCATTCAAATGACACAATACATGATAGGACCCCTTATCGAACCCTATTGATG
AATGAGTTGGGTGTTCCATTTCATTTGGGAACCAGGCAAGTGTGTATAGCATGGTCCAGC
TCAAGTTGTCACGATGGAAAAGCATGGCTGCATGTTTGTGTCACTGGGTATGATAAAAAT
GCAACTGCTAGCTTCATTTACGATGGGAGGCTTGTAGACAGTATTGGTTCATGGTCCAAA
AATATCCTCAGGACCCAGGAGTCGGAATGCGTTTGTATCAATGGGACTTGTACAGTAGTA
ATGACTGATGGAAGTGCTTCAGAAAGAGCTGATACTAAAATACTATTCATTGAAGAGGGG
AAAATCGTTCATATTAGCCCATTGTCAGGAAGTGCTCAGCATGTAGAGGAGTGTTCCTGT
TATCCTCGATATCCTGGTGTCAGATGTGTCTGCAGAGACAACTGGAAAGGCTCCAATAGG
CCCGTCGTAGATATAAATGTGAAAGATTATAGCATTGTTTCCAGTTATGTGTGCTCAGGG
CTTGTTGGCGACACACCCAGAAAAAACGACAGATCTAGCAGTAGCTATTGCCGGAATCCT
AACAATGAGAAAGGGAATCATGGAGTGAAAGGCTGGGCCTTTGACGATGGAAATGACGTG
TGGATGGGAAGAACGATCAGCGAGGAGTCACGATCAGGTTATGAAACCTTCAAAGTCATT
GGTGGTTGGTCCACACCTAATTCCAAATTGCAGATAAATAGGCAAGTCATAGTTGACAGC
GATAATAGGTCCGGTTATTCTGGTATTTTCTCTGTTGAGGGCAAAAGCTGCATCAATAGG
TGCTTTTATGTGGAGTTGATAAGGGGAAGGGAACAGGAAACTAGAGTCTGGTGGACCTCA
AACAGTATTGTTGTGTTTTGTGGCACTTCAGGTACCTATGGAACAGGCTCATGGCCTGAT
GGAGCGGACATCAATCTCATGCCTATATAA

# Drug_Target_1_General_Function:
Involved in exo-alpha-sialidase activity

# Drug_Target_1_General_References:
6196911	Martinez C, del Rio L, Portela A, Domingo E, Ortin J: Evolution of the influenza virus neuraminidase gene during drift of the N2 subtype. Virology. 1983 Oct 30;130(2):539-45.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
64

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
52141

# Drug_Target_1_Name:
Neuraminidase

# Drug_Target_1_Number_of_Residues:
469

# Drug_Target_1_PDB_ID:
2BAT

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_1_Protein_Sequence:
>Neuraminidase
MNPNQKIITIGSVSLTIATICFLMQIAILVTTVTLHFKQYECSSPPNNQVMPCEPIIIER
NITEIVYLTNTTIDKEICPKLVEYRNWSKPQCKITGFAPFSKDNSIRLSAGGGIWVTREP
YVSCDPGKCYQFALGQGTTLDNKHSNDTIHDRTPYRTLLMNELGVPFHLGTRQVCIAWSS
SSCHDGKAWLHVCVTGYDKNATASFIYDGRLVDSIGSWSKNILRTQESECVCINGTCTVV
MTDGSASERADTKILFIEEGKIVHISPLSGSAQHVEECSCYPRYPGVRCVCRDNWKGSNR
PVVDINVKDYSIVSSYVCSGLVGDTPRKNDRSSSSYCRNPNNEKGNHGVKGWAFDDGNDV
WMGRTISEESRSGYETFKVIGGWSTPNSKLQINRQVIVDSDNRSGYSGIFSVEGKSCINR
CFYVELIRGREQETRVWWTSNSIVVFCGTSGTYGTGSWPDGADINLMPI

# Drug_Target_1_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells. Likely to plays a role in the budding process through its association with lipid rafts during intracellular transport. May additionally display a raft-association independent effect on budding. Plays a role in the determination of host range restriction on replication and virulence. Sialidase activity in late endosome/lysosome traffic seems to enhance virus replication

# Drug_Target_1_SwissProt_ID:
P06818

# Drug_Target_1_SwissProt_Name:
NRAM_I79A0

# Drug_Target_1_Synonyms:
EC 3.2.1.18

# Drug_Target_1_Theoretical_pI:
7.28

# Drug_Target_1_Transmembrane_Regions:
7-35

# Drug_Target_2_Cellular_Location:
Virion membrane (By similarity). Apical cell membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
18488077	Eiland LS, Eiland EH: Zanamivir for the prevention of influenza in adults and children age 5 years and older. Ther Clin Risk Manag. 2007 Jun;3(3):461-5.
20695427	Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, Waddington L, Saito T, Tashiro M, McKimm-Breschkin JL: Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses. J Med Chem. 2010 Aug 9.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M54967

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
NA

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
1740114	Burmeister WP, Ruigrok RW, Cusack S: The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 1992 Jan;11(1):49-56.
1984652	Burmeister WP, Daniels RS, Dayan S, Gagnon J, Cusack S, Ruigrok RW: Sequence and crystallization of influenza virus B/Beijing/1/87 neuraminidase. Virology. 1991 Jan;180(1):266-72.
9526556	Taylor NR, Cleasby A, Singh O, Skarzynski T, Wonacott AJ, Smith PW, Sollis SL, Howes PD, Cherry PC, Bethell R, Colman P, Varghese J: Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J Med Chem. 1998 Mar 12;41(6):798-807.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6007

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
51430

# Drug_Target_2_Name:
Neuraminidase

# Drug_Target_2_Number_of_Residues:
465

# Drug_Target_2_PDB_ID:
1A4Q

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_2_Protein_Sequence:
>Neuraminidase
MLPSTIQTLTLFLTSGGVLLSLYVSASLSYLLYSDILLKFSSKITAPTMTLDCANASNVQ
AVNRSATKEMTFLLPEPEWTYPRLSCQGSTFQKALLISPHRFGEARGNSAPLIIREPFIA
CGPKECKHFALTHYAAQPGGYYNGTREDRNKLRHLISVKLGKIPTVENSIFHMAAWSGSA
CHDGREWTYIGVDGPDSNALIKIKYGEAYTDTYHSYANNILRTQESACNCIGGDCYLMIT
DGSASGISKCRFLKIREGRIIKEIFPTGRVEHTEECTCGFASNKTIECACRDNSYTAKRP
FVKLNVETDTAEIRLMCTETYLDTPRPDDGSITGPCESNGDKGRGGIKGGFVHQRMASKI
GRWYSRTMSKTERMGMELYVRYDGDPWTDSDALAHSGVMVSMKEPGWYSFGFEIKDKKCD
VPCIGIEMVHDGGKKTWHSAATAIYCLMGSGQLLWDTVTGVDMAL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells (By similarity)

# Drug_Target_2_SwissProt_ID:
P27907

# Drug_Target_2_SwissProt_Name:
NRAM_INBBE

# Drug_Target_2_Synonyms:
EC 3.2.1.18

# Drug_Target_2_Theoretical_pI:
7.55

# Drug_Target_2_Transmembrane_Regions:
7-35

# Drug_Target_3_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
20222714	Chavas LM, Kato R, Suzuki N, von Itzstein M, Mann MC, Thomson RJ, Dyason JC, McKimm-Breschkin J, Fusi P, Tringali C, Venerando B, Tettamanti G, Monti E, Wakatsuki S: Complexity in influenza virus targeted drug design: interaction with human sialidases. J Med Chem. 2010 Apr 8;53(7):2998-3002.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
NEU2

# Drug_Target_3_GenBank_ID_Gene:
Y16535

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
NEU2

# Drug_Target_3_Gene_Sequence:
>1143 bp
ATGGCGTCCCTTCCTGTCCTGCAGAAGGAGAGCGTGTTCCAGTCGGGAGCCCATGCCTAC
AGAATCCCTGCCCTGCTCTACCTGCCTGGGCAGCAGTCCCTGCTGGCCTTCGCGGAACAG
CGGGCAAGCAAGAAGGATGAGCACGCAGAGCTGATTGTCCTGCGCAGAGGAGACTACGAC
GCACCCACCCACCAGGTTCAGTGGCAAGCTCAGGAGGTGGTGGCCCAGGCCCGGCTGGAT
GGCCACCGGTCCATGAACCCATGCCCCTTGTATGACGCGCAGACGGGGACCCTCTTCCTC
TTCTTCATTGCCATCCCTGGGCAAGTCACGGAGCAACAGCAGCTGCAGACCAGGGCCAAT
GTGACGCGGCTGTGCCAAGTCACCAGCACTGACCACGGGAGGACCTGGAGCTCCCCCAGA
GACCTCACTGATGCGGCCATCGGCCCAGCCTACCGGGAGTGGTCCACCTTTGCAGTGGGC
CCGGGGCATTGTTTGCAGCTTAACGACAGGGCCCGGAGCCTGGTGGTGCCCGCCTACGCC
TACCGGAAACTTCACCCCATCCAAAGGCCGATCCCCTCTGCCTTCTGCTTCCTCAGCCAT
GACCATGGGCGCACGTGGGCGCGAGGGCACTTTGTGGCCCAGGACACCCTGGAGTGCCAG
GTGGCCGAAGTCGAGACTGGGGAGCAGAGGGTGGTGACCCTCAACGCGAGAAGCCACCTC
CGAGCCAGGGTCCAGGCCCAGAGCACCAATGACGGGCTTGATTTCCAGGAGTCTCAGCTG
GTGAAGAAGCTGGTGGAGCCGCCGCCCCAGGGCTGCCAGGGGAGCGTCATCAGCTTCCCC
AGCCCCCGCTCGGGGCCTGGCTCCCCAGCCCAGTGGCTGCTCTACACTCACCCCACACAC
TCCTGGCAGAGGGCCGACCTGGGTGCCTACCTCAACCCGCGACCTCCAGCCCCTGAGGCC
TGGTCAGAGCCGGTACTGCTGGCCAAGGGCAGCTGTGCCTACTCAGACCTCCAGAGCATG
GGCACCGGCCCTGATGGGTCCCCCTTGTTTGGGTGTCTGTACGAAGCCAATGATTACGAG
GAGATTGTCTTTCTCATGTTCACCCTGAAGCAAGCCTTCCCAGCTGAGTACCTGCCTCAG
TGA

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
10191093	Monti E, Preti A, Rossi E, Ballabio A, Borsani G: Cloning and characterization of NEU2, a human gene homologous to rodent soluble sialidases. Genomics. 1999 Apr 1;57(1):137-43.

# Drug_Target_3_HGNC_ID:
HGNC:7759

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
5482

# Drug_Target_3_Locus:
2q37

# Drug_Target_3_Molecular_Weight:
42231

# Drug_Target_3_Name:
Sialidase-2

# Drug_Target_3_Number_of_Residues:
380

# Drug_Target_3_PDB_ID:
1VCU

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02012	BNR

# Drug_Target_3_Protein_Sequence:
>Sialidase-2
MASLPVLQKESVFQSGAHAYRIPALLYLPGQQSLLAFAEQRASKKDEHAELIVLRRGDYD
APTHQVQWQAQEVVAQARLDGHRSMNPCPLYDAQTGTLFLFFIAIPGQVTEQQQLQTRAN
VTRLCQVTSTDHGRTWSSPRDLTDAAIGPAYREWSTFAVGPGHCLQLNDRARSLVVPAYA
YRKLHPIQRPIPSAFCFLSHDHGRTWARGHFVAQDTLECQVAEVETGEQRVVTLNARSHL
RARVQAQSTNDGLDFQESQLVKKLVEPPPQGCQGSVISFPSPRSGPGSPAQWLLYTHPTH
SWQRADLGAYLNPRPPAPEAWSEPVLLAKGSCAYSDLQSMGTGPDGSPLFGCLYEANDYE
EIVFLMFTLKQAFPAEYLPQ

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Hydrolyzes sialylated compounds

# Drug_Target_3_SwissProt_ID:
Q9Y3R4

# Drug_Target_3_SwissProt_Name:
NEUR2_HUMAN

# Drug_Target_3_Synonyms:
Cytosolic sialidase
EC 3.2.1.18
N-acetyl-alpha- neuraminidase 2

# Drug_Target_3_Theoretical_pI:
6.83

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00558
